MedTrace Logo

A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris

NCT00666900 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 366

Last updated 2012-02-20

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and effectiveness of IDP-107 in treating patients with acne vulgaris.

Conditions

  • Acne Vulgaris

Interventions

DRUG

Low Strength IDP-107

Once a day for 12 weeks

DRUG

High Strength IDP-107

Once a day for 12 weeks

DRUG

Placebo Comparator

Once a day for 12 weeks

Sponsors & Collaborators

  • Dow Pharmaceutical Sciences

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2009-03-31
Completion
2009-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00666900 on ClinicalTrials.gov